Rationale: Ibrutinib, a Bruton tyrosine kinase inhibitor, is widely used in chronic lymphocytic leukemia (CLL). Its association with secondary hemophagocytic lymphohistiocytosis (HLH) is exceedingly rare but potentially fatal. Patient concerns: A 59-year-old male with CLL presented with recurrent fever and progressive splenomegaly. Diagnoses: Bone marrow biopsy confirmed CLL. Five months after ibrutinib (420 mg/day) initiation, progressive pancytopenia, hyperferritinemia, and hemophagocytosis on repeat marrow aspirate established HLH diagnosis. Interventions: HLH-94 protocol (etoposide + dexamethasone) was initiated. Outcomes: The patient developed fungemia followed by massive cerebral infarction. Treatment was withdrawn due to deterioration, resulting in death. Lessons: Ibrutinib may trigger HLH via immune dysregulation. Early recognition through vigilant monitoring of cytopenias, ferritin, and marrow hemophagocytosis is critical to improve survival.
Hou et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: